ClinicalTrials.gg
CompletedNCT05831111Updated Nov 4, 2026

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

A Phase 1 interventional study of mRNA-1195.1 and mRNA-1195.2 in Epstein-Barr Virus Infection, sponsored by ModernaTX, Inc.. Completed at 34 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention

Updated Nov 4, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Epstein-Barr Virus Infections with a site in United States — 19 open to participants now, 25 under way, 2 of them phase 3. Epstein-Barr Virus Infections · United States.

Enrollment
6th of 63
482 · median 25
Started
2023
with 3 others
Phase 1
19 of 76
8 open now
Registered
67th of 76
by date
Lead sponsor
2 of 76
ModernaTX, Inc.

Among the 76 studies in Epstein-Barr Virus Infections with a site in United States, this one is the 6th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2023, is one of 19 in phase 1, and was the 67th registered.

Epstein-Barr Virus Infections

175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.

Browse Epstein-Barr Virus Infections studies →

Open to participants now

19 of the 76 studies in Epstein-Barr Virus Infections with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Epstein-Barr Virus Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Read the detailed description

There will be 2 sequential parts to the study:

  • Participants 18 through 55 years of age will be enrolled in Part A of the study first, which will only enroll those participants who are EBV-seropositive at Screening.
  • Part B will enroll participants 18 through 30 years of age who are either EBV-seronegative or EBV-seropositive at Screening.
03

Conditions studied

  • Epstein-Barr Virus Infection

Keywords

  • Infectious mononucleosis
  • Mononucleosis
  • Virus Diseases
  • Infections
  • Gamma-herpesvirus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • For Part A: Positive EBV serostatus at Screening. For Part B: Negative EBV serostatus or Positive EBV serostatus at Screening.
  • According to the assessment of the Investigator, is in good general health and can comply with study procedures.
  • For participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 3 months following last study injection and is not currently breast/chest feeding.

Key Exclusion Criteria:

  • Participant is acutely ill or febrile (temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
  • Symptomatic acute or chronic illness requiring ongoing medical or surgical care, to include changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the Investigator).
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • History of myocarditis, pericarditis, or myopericarditis.
  • Participant has received systemic or immune-modifying drugs for >14 days in total within 6 months prior to Screening Visit (for ≥10 milligrams [mg]/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. Topical corticosteroids and tacrolimus are allowed.
  • Participant has received or plans to receive any licensed or authorized vaccine, to include COVID-19 vaccines, ≤28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study injection, with the exception of licensed/authorized influenza vaccines, which may be received more than 14 days before or after any study injection.
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
482 participants (actual)

Study arms

  • Experimental
    Part A: mRNA-1195.1 Dose Level 1

    Participants will receive 3 intramuscular (IM) injections of mRNA-1195.1 at Dose Level 1 on Days 1, 57, and 169.

    Biological: mRNA-1195.1

  • Experimental
    Part A: mRNA-1195.2 Dose Level 1

    Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 1 on Days 1, 57, and 169.

    Biological: mRNA-1195.2

  • Experimental
    Part A: mRNA-1195.1 Dose Level 2

    Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 2 on Days 1, 57, and 169.

    Biological: mRNA-1195.1

  • Experimental
    Part A: mRNA-1195.2 Dose Level 2

    Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 2 on Days 1, 57, and 169.

    Biological: mRNA-1195.2

  • Experimental
    Part A: mRNA-1195.1 Dose Level 3

    Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 3 on Days 1, 57, and 169.

    Biological: mRNA-1195.1

  • Experimental
    Part A: mRNA-1195.2 Dose Level 3

    Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 3 on Days 1, 57, and 169.

    Biological: mRNA-1195.2

  • Experimental
    Part A: mRNA-1195.1 Dose Level 4

    Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 4 on Days 1, 57, and 169.

    Biological: mRNA-1195.1

  • Experimental
    Part A: mRNA-1195.2 Dose Level 4

    Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 4 on Days 1, 57, and 169.

    Biological: mRNA-1195.2

  • Active comparator
    Part A: mRNA-1189

    Participants will receive 3 IM injections of mRNA-1189 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Placebo comparator
    Part A: Placebo

    Participants will receive 3 IM injections of study drug-matching placebo on Days 1, 57, and 169.

    Biological: Placebo

  • Placebo comparator
    Part B: Placebo

    Participants will receive 3 IM injections of study drug-matching placebo on Days 1, 57, and 169.

    Biological: Placebo

  • Experimental
    Part B: mRNA-1195 Low Dose

    Participants will receive 3 IM injections of mRNA-1195 (at a dose level selected based on the Part A interim analysis) low dose on Days 1, 57, and 169.

    Biological: mRNA-1195

  • Experimental
    Part B: mRNA-1195 Middle Dose

    Participants will receive 3 IM injections of mRNA-1195 (at a dose level selected based on the Part A interim analysis) middle dose on Days 1, 57, and 169.

    Biological: mRNA-1195

  • Experimental
    Part B: mRNA-1195 High Dose

    Participants will receive 3 IM injections of mRNA-1195 (at a dose level selected based on the Part A interim analysis) high dose on Days 1, 57, and 169.

    Biological: mRNA-1195

Interventions

  • BiologicalmRNA-1195.1

    Sterile liquid for injection

  • BiologicalmRNA-1195.2

    Sterile liquid for injection

  • BiologicalmRNA-1189

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

  • BiologicalmRNA-1195

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

    Time frame: Up to Day 176 (7-day follow-up after vaccination)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 197 (28-day follow-up after vaccination)

  3. Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Discontinuation of Study Intervention and/or Study Participation, and AEs of Special Interest (AESIs)

    Time frame: Part A and B: Day 1 to end of study (EOS) (Part A: Day 337; Part B: Day 505)

Secondary outcomes

  1. Geometric Mean Titer (GMT) of B-Cell Neutralizing Antibody (nAb) and/or Antigen-Specific Binding Antibody (bAb)

    Time frame: Days 1, 85, and 197

  2. Geometric Mean Fold Rise (GMFR) of B-Cell nAb and/or Antigen-Specific bAb

    Time frame: Days 1, 85, and 197

  3. Number of Participants With Seroresponse of B-Cell nAbs and/or Antigen-Specific bAbs

    Time frame: Days 1, 85, and 197

07

Study locations

34 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Tekton Research
    Longmont, Colorado 80501, United States
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • Velocity Clinical Research
    Savannah, Georgia 31406, United States
  • DM Clinical Research- Chicago
    Melrose Park, Illinois 60160, United States
  • Optimal Research
    Peoria, Illinois 61614, United States
  • Velocity Clinical Research
    Sioux City, Iowa 51106, United States
  • Johnson County Clin-Trials, Inc (JCCT)
    Lenexa, Kansas 66219, United States
  • Velocity Clinical Research
    Rockville, Maryland 20854, United States
  • DM Clinical Research
    Brookline, Massachusetts 02445, United States
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
  • DM Clinical Research
    Southfield, Michigan 48076, United States
  • Velocity Clinical Research
    Grand Island, Nebraska 68803, United States
  • Velocity Clinical Research
    Hastings, Nebraska 68901, United States
  • Velocity Clinical Research
    Lincoln, Nebraska 68510, United States
  • Velocity Clinical Research
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research
    Omaha, Nebraska 68134, United States
  • Las Vegas Clinical Trials, LLC
    North Las Vegas, Nevada 89030, United States
  • Velocity Clinical Research
    Binghamton, New York 13905, United States
  • Rochester Clinical Research, Inc
    Rochester, New York 14609, United States
  • Eximia Clinical Research
    Raleigh, North Carolina 27607, United States
  • Tekton Research, Inc
    Edmond, Oklahoma 73013, United States
  • Tekton Research
    Moore, Oklahoma 73160, United States
  • Tekton Research
    Oklahoma City, Oklahoma 73134, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Tekton Research Inc.
    Austin, Texas 78745, United States
  • DM Clinical Research
    Houston, Texas 77065, United States
  • 3A Research
    Plano, Texas 75093, United States
  • DM Clinical Research
    Sugar Land, Texas 77478, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Oct 2026, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
Apr 26, 2023
StartActual
Apr 5, 2023
Primary completionActual
Oct 14, 2026
CompletionActual
Oct 14, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Primary completion
Oct 13, 2026→Oct 14, 2026 (actual)
Nov 4, 2026
Study completion
Oct 13, 2026→Oct 14, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Completed
    Primary completion Oct 13, 2026→Oct 14, 2026 (now actual)
    Study completion Oct 13, 2026→Oct 14, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05831111
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
Apr 5, 2023
Primary completion
Oct 14, 2026
Completion
Oct 14, 2026
Last update
Nov 4, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion